Morris Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Morris Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3M	Sell	4,347 -56	-1%	-$35.2K	2.82%	13
2022 Q2	$2.6M	Buy	4,403 +78	+2%	+$50.7K	2.32%	22
2022 Q1	$3.02M	Sell	4,325 -94	-2%	-$59.5K	2.35%	19
2021 Q4	$2.79M	Sell	4,419 -55	-1%	-$33.8K	2.05%	21
2021 Q3	$2.71M	Sell	4,474 -124	-3%	-$77K	2.13%	21
2021 Q2	$2.57M	Buy	4,598 +110	+2%	+$55.7K	1.94%	24
2021 Q1	$2.12M	Sell	4,488 -116	-3%	-$56.5K	1.72%	27
2020 Q4	$2.22M	Sell	4,604 -287	-6%	-$155K	1.83%	25
2020 Q3	$2.74M	Sell	4,891 -251	-5%	-$152K	2.42%	15
2020 Q2	$3.21M	Sell	5,142 -167	-3%	-$94.8K	2.89%	12
2020 Q1	$2.59M	Buy	+5,309	New	+$2.19M	2.77%	13

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morris Capital Advisors's REGN Position: Q3 2022 in Review

Morris Capital Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 1.3% in Q3 2022, selling an estimated $35.2K and leaving 4,347 shares worth $3M. The position accounts for 2.82% of the portfolio, ranked #13.

Morris Capital Advisors first reported a position in REGN in Q1 2020 and has held it in 11 quarters since. The position peaked at $3.21M in Q2 2020. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Morris Capital Advisors held 4,347 shares of Regeneron Pharmaceuticals worth $3M as of Q3 2022.
Morris Capital Advisors sold 56 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $35.2K.
Regeneron Pharmaceuticals made up 2.82% of Morris Capital Advisors's portfolio in Q3 2022, its #13 holding.
Morris Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 11 quarters since.
Morris Capital Advisors's Regeneron Pharmaceuticals position peaked at $3.21M in Q2 2020.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Morris Capital Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.